Inventor
DUERR HARALD
DE13 patents
⚠️ This page may combine multiple inventors who share the name “DUERR HARALD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HOFFMANN LA ROCHE
10 patentsUS11603411B2Mar 14, 2023
Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
HOFFMANN LA ROCHE9 citations85
US10941205B2Mar 9, 2021
Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
HOFFMANN LA ROCHE10 citations85
US11242396B2Feb 8, 2022
Bispecific antigen binding molecules comprising anti-FAP clone 212
HOFFMANN LA ROCHE14 citations82
US11787868B2Oct 17, 2023
Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
HOFFMANN LA ROCHE1 citations72
US12358997B1Jul 15, 2025
Bispecific anti-human A-beta/anti-human transferrin receptor antibodies
HOFFMANN LA ROCHE0 citations62
US12030952B2Jul 9, 2024
Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
HOFFMANN LA ROCHE1 citations62
US12275794B2Apr 15, 2025
Bispecific antigen binding molecules comprising anti-FAP clone 212
HOFFMANN LA ROCHE0 citations59
US11780919B2Oct 10, 2023
Bispecific antigen binding molecules targeting OX40 and FAP
HOFFMANN LA ROCHE1 citations56
US12145994B2Nov 19, 2024
Bispecific antigen binding molecules capable of specific binding to CD40 and to fap
HOFFMANN LA ROCHE0 citations46
US10316059B2Jun 11, 2019
Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
HOFFMANN LA ROCHE0 citations33
ROCHE GLYCART AG
2 patentsUS9695233B2Jul 4, 2017
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
ROCHE GLYCART AG44 citations97
US10683345B2Jun 16, 2020
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
ROCHE GLYCART AG5 citations72